Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients (2018)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1007/s12029-017-0001-3
- Subjects: NEOPLASIAS COLORRETAIS; METÁSTASE NEOPLÁSICA; QUIMIOTERAPIA COMBINADA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of gastrointestinal cancer
- ISSN: 1941-6628
- Volume/Número/Paginação/Ano: v. 49, n. 4, p. 470-475, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FERNANDES, Gustavo Dos Santos et al. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients. Journal of gastrointestinal cancer, v. 49, n. 4, p. 470-475, 2018Tradução . . Disponível em: https://doi.org/10.1007/s12029-017-0001-3. Acesso em: 09 fev. 2026. -
APA
Fernandes, G. D. S., Braghiroli, M. I., Artioli, M., Paterlini, A. C. C. R., Teixeira, M. C., Gumz, B. P., et al. (2018). Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients. Journal of gastrointestinal cancer, 49( 4), 470-475. doi:10.1007/s12029-017-0001-3 -
NLM
Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi D da M, Braghiroli OFM, Costa FP, Hoff PMG. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients [Internet]. Journal of gastrointestinal cancer. 2018 ; 49( 4): 470-475.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1007/s12029-017-0001-3 -
Vancouver
Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi D da M, Braghiroli OFM, Costa FP, Hoff PMG. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients [Internet]. Journal of gastrointestinal cancer. 2018 ; 49( 4): 470-475.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1007/s12029-017-0001-3 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre o DOI: 10.1007/s12029-017-0001-3 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
